Published in Gene Therapy Weekly, July 12th, 1999
One U.S. patent claims a modified adenovirus that may be used as a therapeutic to introduce genetic constructs that are toxic to prostate cancer cells in a highly targeted and specific manner. The other patent claims a human prostate-specific transcriptional regulatory sequence, the polynucleotides that comprise such regions, the toxin gene that is controlled by the regulatory sequence, and methods for treating prostate disease using toxin gene constructs.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.